Welcome to LookChem.com Sign In|Join Free

CAS

  • or

56392-17-7

Post Buying Request

56392-17-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

56392-17-7 Usage

β1 receptor blocker

Metoprolol tartrate is a selective β1-adrenergic receptor blocker,oral absorption is rapid? and complete,it is used for the treatment of hypertension, angina pectoris, myocardial infarction, hypertrophic cardiomyopathy, aortic dissection, cardiac arrhythmia, hyperthyroidism, cardiac neurosis and other diseases. In recent years, it is also used for ther treatment of heart failure, which can reduce mortality. In unstable/non-ST-segment elevation myocardial infarction and acute myocardial infarction? control guiding principles developed by American Heart Association , effect of metoprolol tartrateare is clearly recognized. In the past, concerns about β-blocker therapy caused hypotension is too large, and for the consideration that there may be racial differences between Asians in β-blocker use and the West, patients with treatment of β-blockers in China is? fewer? , the use of β-blockers is in lower dose. Metoprolol tartrate has a weaker membrane stability and it has no intrinsic sympathomimetic activity, and in comparison with similar drugs commonly used in clinical propranolol ,in addition to the advantages of β1-blocker on its pharmacodynamic,it also has its pharmacokinetic kinetics? advantages, such as relatively weak first-pass effect compared with propranolol, simple metabolic pathways, most pharmacologically inactive metabolites and the like.

Uses

Different sources of media describe the Uses of 56392-17-7 differently. You can refer to the following data:
1. Hypertensive medication.
2. A ? selective aryloxypropanolamine andrenergic antagonist. Used in the treatment of a variety of cardiovascular disorder. Antihypertensive; antianginal; antiarrhythmic (class II)
3. A β1 selective aryloxypropanolamine andrenergic antagonist. Used in the treatment of a variety of cardiovascular disorder. Antihypertensive; antianginal; antiarrhythmic (class II).
4. alpha(1)-adrenergic blocker
5. A b1-Adrenergic blocker
6. Metoprolol tartrate is an antagonist of the β1-AR (β1-adrenoceptor). It inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo.

Hazards & Safety Information

Category: toxic substances Toxicity grading: Middle? poisoning Acute toxicity: oral?-rat LD50: 5500 mg/kg; Oral-Mouse LD50: 1500 mg/kg Flammability and hazard characteristics: It is combustible; fire decomposition produces toxic nitrogen oxide gases Storage Characteristics: Ventilated, low-temperature ,dry storeroom. Extinguishing agent: Water, carbon dioxide, dry powder, sandy soil.

Description

Metoprolol (tartrate) (Item No. 21165) is an analytical reference standard categorized as a β1-adrenergic receptor blocker. This product is intended for use in analytical forensic applications. Metoprolol (succinate) is available as a general research tool .

Chemical Properties

White or almost white, crystalline powder or colourless crystals.

Therapeutic Function

Beta-adrenergic blocker

General Description

A certified solution standard applicable for use in clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Metoprolol is used for the treatment of multiple heart conditions including hypertension, angina, and tachycardia. This beta blocker is sold under the trade names Lepressor and Toprol XL?.

Biological Activity

Selective β 1 -adrenoceptor antagonist (K i values are 47, 2960 and 10100 nM for β 1 , β 2 and β 3 adrenoceptors respectively). Inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo .

Clinical Use

Beta-adrenoceptor blocker: Hypertension Angina Cardiac arrhythmias Migraine prophylaxis Hyperthyroidism

Veterinary Drugs and Treatments

Because metoprolol is relatively safe to use in animals with bronchospastic disease, it is often chosen over propranolol. It may be effective in supraventricular tachyarrhythmias, premature ventricular contractions (PVC’s, VPC’s), systemic hypertension, and treating cats with hypertrophic cardiomyopathy. There is increasing interest in using beta blockers in heart failure in dogs; one retrospective study showed increased survival times when dogs were given metoprolol, but definitive prospective, double-blinded studies have not been reported documenting the benefit (increased survival) of beta-blockers in dogs with heart failure.

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: NSAIDs antagonise hypotensive effect. Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide; concentration increased by propafenone and dronedarone. Antibacterials: concentration reduced by rifampicin. Antidepressants: enhanced hypotensive effect with MAOIs; concentration increased by citalopram and escitalopram and possibly by paroxetine - avoid. Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin. Antimalarials: increased risk of bradycardia with mefloquine; avoid with artemether/lumefantrine. Antipsychotics enhanced hypotensive effect with phenothiazines. Antivirals: avoid concomitant use with tipranavir in heart failure. Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil. Cytotoxics: possible increased risk of bradycardia with crizotinib. Diuretics: enhanced hypotensive effect. Fingolimod: possibly increased risk of bradycardia. Moxisylyte: possible severe postural hypotension.

Metabolism

Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP2D6, and undergoes oxidative deamination, O-dealkylation followed by oxidation, and aliphatic hydroxylation. The metabolites are excreted in the urine with only small amounts of unchanged metoprolol.

Check Digit Verification of cas no

The CAS Registry Mumber 56392-17-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,3,9 and 2 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 56392-17:
(7*5)+(6*6)+(5*3)+(4*9)+(3*2)+(2*1)+(1*7)=137
137 % 10 = 7
So 56392-17-7 is a valid CAS Registry Number.

56392-17-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Cerilliant

  • (M-123)  Metoprolol tartrate solution  1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material

  • 56392-17-7

  • M-123-1ML

  • 366.21CNY

  • Detail
  • Sigma-Aldrich

  • (80337)  (±)-Metoprolol (+)-tartrate salt  analytical standard

  • 56392-17-7

  • 80337-100MG

  • 595.53CNY

  • Detail

56392-17-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name rac Metoprolol Hemi (+)-Tartrate

1.2 Other means of identification

Product number -
Other names Metoprolol tartrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:56392-17-7 SDS

56392-17-7Relevant articles and documents

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE

-

, (2015/02/05)

To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.

Metoprolol manufacturing process

-

Page/Page column 3, (2010/02/11)

Metoprolol manufacturing process with optimized reaction temperatures and reactant molar ratios, to avoid the manufacture of excessive epoxide intermediates, thus avoiding the need for purification of epoxide intermediates, thus achieving higher yields and higher-purity product than that seen in the prior art teachings.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 56392-17-7